The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

USA: Researchers have found in a new retrospective cohort study that SGLT2 inhibitor use before emergency surgery in patients ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...